GENE ONLINE|News &
Opinion
Blog

AstraZenca
COVID-19
Weekly Cover: Expansion of Samsung Biologics Projects into U.S. and Europe
2020-02-11
Weekly in Asia｜Dec-3
2020-01-02
Weekly in Asia｜Dec-1
2019-12-17
R&D Asthma
Astra Zeneca to Resume Rivalry with Old Competitor Following Key Win for FASENRA®
2019-10-14
EGFR
Weekly in Asia | SEP-1
2019-09-17
CDK4/6
Weekly in Asia 2019｜AUG-3
2019-08-25
Trials & Approvals ATM
Lynparza Meets Primary Endpoint in Phase III PROfound Trial
2019-08-16
BIO Asia Taiwan Review: The AI Tide, How Informatics Shape the Future of Pharmaceutical Industry
2019-08-12
Trials & Approvals Ovarian Cancer
First PARP inhibitor approved for 1L maintenance therapy of BRCAm advanced ovarian cancer
2018-12-28
Homegrown Oncology Drug
Fruquintinib becomes the first homegrown oncology drug approved in China for major indication
2018-09-11
In-Depth Breast Cancer
PARP inhibitors in cancer – BRCA or no BRCA
2018-07-03
1 … 3 4 5
LATEST
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top